Cholinergic Drugs in Pharmacotherapy of Alzheimers Disease

Author(s): Pelayo Camps, Diego Munoz-Torrero

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 2 , Issue 1 , 2002

Become EABM
Become Reviewer


The cholinergic hypothesis of Alzheimers disease has spurred the development of numerous structural classes of compounds with different pharmacological profiles aimed at increasing central cholinergic neurotransmission, thus providing a symptomatic treatment for this disease. Indeed, the only drugs currently approved for the treatment of Alzheimers disease are cholinomimetics with the pharmacological profile of acetylcholinesterase inhibitors. Recent evidence of a potential disease modifying role of acetylcholinesterase inhibitors and M1 muscarinic agonists have led to a revival of this approach, which might be considered as more than a symptomatic treatment.

Keywords: Cholinergic Drugs, Alzheimers disease, muscarinic agonists, acetylcholine (ACh), Potassium Channel Blockers, Aminoacridines, N-Benzylpiperidines, xanomeline, muscarine

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [11 - 25]
Pages: 15
DOI: 10.2174/1389557023406638

Article Metrics

PDF: 37